Mimedx (MDXG) Cash from Financing Activities (2011 - 2026)
Mimedx (MDXG) reported Cash from Financing Activities of -$2.6 million for Q1 2026, up 10.18% on a YoY basis from -$2.3 million in Q1 2025, and down 343.4% sequentially from -$583000.0 in Q4 2025.
Mimedx (MDXG) Cash from Financing Activities (2011 - 2026) Analysis & Trends
Mimedx (MDXG) has 16 years of Cash from Financing Activities data on file, last reported at -$2.6 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 10.18% year-over-year to -$2.6 million; the trailing twelve-month figure through Mar 2026 stood at -$5.1 million (down 41.8% YoY), and the FY2025 full-year result was -$5.4 million, up 84.17% from the prior year.
- Cash from Financing Activities fell to -$2.6 million in Q1 2026, from -$583000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $370000.0 in Q3 2023 to a low of -$33.5 million in Q1 2024.
- A 5-year average of -$3.0 million and a median of -$400000.0 in 2024 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities surged 200.0% in 2022 and sank 836575.0% in 2024, its largest moves.
- Tracing MDXG's Cash from Financing Activities over 5 years: stood at $66000.0 in 2022, then sank by 13645.45% to -$8.9 million in 2023, then jumped by 95.53% to -$400000.0 in 2024, then plunged by 45.75% to -$583000.0 in 2025, then sank by 343.4% to -$2.6 million in 2026.
- Business Quant data shows MDXG's Cash from Financing Activities at -$2.6 million in Q1 2026, -$583000.0 in Q4 2025, and -$857000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Mimedx | 615.09 Mn | 455.31 Mn | 41.62 Mn | -2.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.59 Mn |
| Mar 31, 2026 | -2.59 Mn |
| Dec 31, 2025 | -583,000.00 |
| Dec 31, 2025 | -583,000.00 |
| Sep 30, 2025 | -857,000.00 |
| Sep 30, 2025 | -857,000.00 |
| Jun 30, 2025 | -1.09 Mn |
| Jun 30, 2025 | -1.09 Mn |
| Mar 31, 2025 | -2.88 Mn |
| Mar 31, 2025 | -2.88 Mn |
| Dec 31, 2024 | -400,000.00 |
| Dec 31, 2024 | -400,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Jun 30, 2024 | -359,000.00 |
| Jun 30, 2024 | -359,000.00 |
| Mar 31, 2024 | -33.47 Mn |
| Mar 31, 2024 | -33.47 Mn |
| Dec 31, 2023 | -8.94 Mn |
| Dec 31, 2023 | -8.94 Mn |